Journal
UROLOGIA INTERNATIONALIS
Volume 100, Issue 1, Pages 66-71Publisher
KARGER
DOI: 10.1159/000479187
Keywords
Eligard (R); Leuprolide; Non-interventional studies; Prospective study on cancer
Categories
Funding
- Astellas Pharma GmbH, Germany
- Astellas Pharma GmbH
- Astellas Pharma, Inc.
Ask authors/readers for more resources
Introduction: We evaluated the efficacy and tolerability of 3- and 6-month leuprorelin acetate (LA) depot formulations (Eligard (R), Astellas Pharma GmbH) in patients with advanced prostate cancer treated in routine clinical practice in Germany. Materials and Methods: Data was pooled from 2 prospective, open-label, non-interventional studies in which 1,906 patients were treated for 12 months with either the 3-month (n = 633) or 6-month (n = 1,273) LA formulation. Results: Median prostate-specific antigen levels in the pooled patient population declined from 12.0 ng/mL at baseline to 0.5 ng/mL after 12 months. Prostate-specific antigen reduction was achieved in treatment-naive and pre-treated patients. Adverse events were documented in 8.8% of patients. Conclusions: These pooled data from routine clinical practice in Germany indicate that LA 3- and 6-month depot injections can effectively reduce prostate-specific antigen levels in a broad patient population with advanced prostate cancer. (c) 2017 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available